Susquehanna International Group
NAVB

Susquehanna International Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Susquehanna International Group’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-185,200
Closed -$324K – 14532
2021
Q3 		$324K Buy
185,200
+11,500
+7% +$19.4K ﹤0.01% 10429
2021
Q2 		$318K Buy
173,700
+63,900
+58% +$113K ﹤0.01% 10656
2021
Q1 		$222K Buy
109,800
+38,300
+54% +$89.6K ﹤0.01% 11218
2020
Q4 		$154K Buy
71,500
+37,700
+112% +$88.9K ﹤0.01% 10237
2020
Q3 		$91K Buy
+33,800
New +$121K ﹤0.01% 9964
2020
Q1 		– Sell
-15,100
Closed -$19K – 11389
2019
Q4 		$19K Sell
15,100
-500
-3% -$432 ﹤0.01% 9494
2019
Q3 		$11K Buy
15,600
+2,900
+23% +$1.78K ﹤0.01% 10016
2019
Q2 		$8K Buy
+12,700
New +$24.6K ﹤0.01% 10090
2018
Q1 		– Sell
-550
Closed -$4K – 10685
2017
Q4 		$4K Sell
550
-1,135
-67% -$9.6K ﹤0.01% 9135
2017
Q3 		$14K Sell
1,685
-870
-34% -$7.37K ﹤0.01% 8677
2017
Q2 		$26K Sell
2,555
-895
-26% -$8.85K ﹤0.01% 8991
2017
Q1 		$40K Sell
3,450
-250
-7% -$2.84K ﹤0.01% 8631
2016
Q4 		$47K Buy
3,700
+1,275
+53% +$20.2K ﹤0.01% 9304
2016
Q3 		$44K Buy
2,425
+1,705
+237% +$21.6K ﹤0.01% 8164
2016
Q2 		$8K Buy
720
+15
+2% +$295 ﹤0.01% 8431
2016
Q1 		$13K Sell
705
-306,065
-100% -$5.89M ﹤0.01% 8860
2015
Q4 		$8.16M Buy
306,770
+770
+0.3% +$26.7K ﹤0.01% 1962
2015
Q3 		$14M Buy
306,000
+230
+0.1% +$8.67K 0.01% 1520
2015
Q2 		$9.91M Buy
305,770
+55
+0% +$1.6K ﹤0.01% 2012
2015
Q1 		$9.72M Sell
305,715
-6,780
-2% -$229K ﹤0.01% 1910
2014
Q4 		$11.8M Sell
312,495
-1,145
-0.4% -$31.5K ﹤0.01% 1852
2014
Q3 		$8.28M Sell
313,640
-2,580
-0.8% -$68.3K ﹤0.01% 2320
2014
Q2 		$9.36M Sell
316,220
-2,555
-0.8% -$82.6K ﹤0.01% 2198
2014
Q1 		$11.8M Buy
318,775
+302,880
+1,906% +$11.5M 0.01% 1820
2013
Q4 		$658K Buy
15,895
+2,565
+19% +$100K ﹤0.01% 6256
2013
Q3 		$706K Sell
13,330
-5,990
-31% -$349K ﹤0.01% 5884
2013
Q2 		$1.03M Buy
+19,320
New +$965K ﹤0.01% 4935

Other funds holding NAVB

ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group's NAVB Position: Q3 2023 in Review

Susquehanna International Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2023, closing a stake of 125,866 shares — an estimated $11.6K sold.

Susquehanna International Group first reported a position in NAVB in Q2 2013 and held it in 25 quarters. The position peaked at $14.2M in Q3 2015. 24 funds tracked by Wall St. Rank hold NAVB as of Q3 2023.

  • Susquehanna International Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2023 after selling out during the quarter.
  • Susquehanna International Group sold 125,866 Navidea Biopharmaceuticals Inc. shares in Q3 2023, an estimated $11.6K.
  • Susquehanna International Group first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 25 quarters.
  • Susquehanna International Group's Navidea Biopharmaceuticals Inc. position peaked at $14.2M in Q3 2015.
  • 24 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.